Treace Medical prelim Q4 rev $33.1-33.4M, FY rev $94.1-94.4M (+64-65% YoY)

TREACE MEDICAL CONCEPTS, INC.

2022-FY EPS reported -$0.43 revenue$94,419,000

Preliminary Q4 2021 revenue $33.1M-$33.4M (up 37-39% YoY); FY 2021 revenue $94.1M-$94.4M (up 64-65% YoY).
Full-year revenue at high end of prior guidance range of $90M-$95M.
Sequential Q4 revenue growth of 53-54% vs Q3 2021.
CEO cites strength of direct sales channel, DTC, and surgeon training programs.
Company to provide 2022 financial guidance on Q4 earnings call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.